Strategic Biotech Reallocation
Avidity Partners Increases Perspective Therapeutics Stake Amid Broad Institutional Trading Shifts
Key Points
In Perspective Therapeutics (CATX), Avidity reported it held 3,210,733 shares after buying an additional 216,700 shares in the quarter, and institutional investors own 54.66% of CATX’s stock—suggesting the reallocations are happening alongside broad market participation.
Perspective Therapeutics also received fresh sell-side support: UBS raised its price objective to $8.00 and assigned a “buy” rating, while B. Riley Financial lifted its target from $11.00 to $13.00—an additional signal of shifting sentiment beyond Avidity’s own buys.
For Context Therapeutics (CNTX), beyond the position trim, Avidity disclosed it owned about 5.99% of the company as of its most recent SEC filing—an investor concentration level not captured in the summary.
Other institutions’ moves in CNTX were dramatic: Marshall Wace LLP increased its stake by 7,153.7% to 2,593,198 shares (valued at $3,812,000), indicating unusually aggressive repositioning by peers even as Avidity reduced exposure.
In Dianthus Therapeutics (DNTH), Avidity said the holding accounted for approximately 25.0% of its investment portfolio even after trimming 34.3%—i.e., it remained a dominant portfolio allocation despite the reduction.
Avidity Partners Management LP quietly reshuffled its healthcare portfolio in Q1 2026, buying more shares of Perspective Therapeutics while trimming two other biotech bets. The Dallas-based hedge fund now holds 3,210,733 shares of Perspective Therapeutics (CATX) — a 7.2% increase — making it the firm's 8th largest position at roughly $8.8 million, according to Ticker Report.
The moves come as Avidity's assets under management have fallen sharply — from over $3 billion in early 2024 to about $936 million in 2026, per Stockzoa. The firm is betting on a smaller set of high-conviction names as clinical catalysts pile up across its portfolio.
Avidity Doubles Down on Perspective Despite 2025 Selloff
Perspective Therapeutics had a rough 2025. UBS cut its price target from $18.00 to $7.00 in November after a competitor reported stronger efficacy data in neuroendocrine tumors. But in March 2026, sentiment shifted. UBS raised its target back to $8.00 and assigned a
Avidity's buy lands alongside broad institutional interest. According to MarketBeat, institutional investors now own 54.66% of CATX's outstanding shares. The stock's $271 million cash runway and upcoming registration-enabling studies are key reasons analysts see the worst as over.
Dianthus Stays King Despite a 34% Portfolio Trim
Avidity cut its Dianthus Therapeutics (DNTH) stake by 34.3%, dropping to about 2.1 million shares. Yet DNTH still makes up roughly 25% of the firm's entire portfolio — worth around $86.7 million. LevelFields AI called it a
The trim looks like risk management after a strong run, not a loss of faith. Holding a quarter of your fund in one stock is still an aggressive bet. Avidity is simply shaving the edges of its biggest position, not walking away from it.
Marshall Wace Storms Into Context Therapeutics as Avidity Exits
In Context Therapeutics (CNTX), Avidity went the other way — cutting its stake by 38.7% to about 5.5 million shares, a position worth roughly $8.1 million. Avidity still owns about 5.99% of the company, per its most recent SEC filing. The trim follows a $100 million private placement Avidity helped lead back in May 2024.
While Avidity pulled back, Marshall Wace LLP charged in. The quant fund increased its CNTX stake by 7,153.7%, jumping to 2,593,198 shares valued at $3.81 million, according to Context Q4 Filings. Analysts see the move as an aggressive bet on Phase 1a data for CNTX's lead drug candidate, expected in June 2026.
Avidity Opens Fresh Position in Beaten-Down Acadia Healthcare
Avidity also opened a brand-new position in Acadia Healthcare (ACHC), buying 169,000 shares worth about $2.4 million. Acadia reported a massive $1.1 billion non-cash goodwill impairment in February 2026, according to Acadia Healthcare. That kind of write-down often signals a stock has hit bottom — exactly the type of recovery play Avidity is known for.
CEO Debbie Osteen has described the company's current focus as
Sentiment
Mostly PositivePublishers
15
Articles
11
Reach
26
